Jul 17, 2008

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease

This is a Phase III clinical trial and the study is currently recruiting participants.

This is a multi center, double-blind, placebo controlled, randomized, outpatient multiple dose study in male and female patients aged 50 to 89 years with mild to moderate AD. Approximately 200 study sites in the US and Canada will be involved. Patients will be randomized to receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.

You can get all the specifics on this Phase III clinical trial at Clinical Trials.gov.

For a quick look at the locations participating in the study go to Locations

You can visit the Elan website to learn more about Bapineuzumab